Bayer's Pharma Beat Wins Two Fresh Bull Calls, but the Margin Is Only Half the Story

Two of the Street's biggest houses moved in the same direction on Bayer today, and neither changed its rating to get there. Goldman Sachs lifted its price target to EUR 66 from EUR 63.50, and UBS followed to EUR 66 from EUR 62, both keeping a Buy recommendation. The shares responded in kind, climbing 4.5% on the session.

The trigger was a third-quarter report that landed yesterday and a guidance raise that followed it. Group revenue for the quarter came in at EUR 10.053 billion, with EBITDA before special items of EUR 1.615 billion. Bayer pointed to its pharmaceuticals business — Nubeqa and Kerendia above all — as the main force behind the improved full-year outlook, a read confirmed by Reuters.

What the Pharma Numbers Actually Show

The division posted revenue of EUR 4.680 billion, while EBITDA before special items jumped 23.6% to EUR 1.292 billion. Adjusted group earnings per share reached EUR 0.31. Nubeqa's quarterly sales rose 58.3% to roughly EUR 998 million, and Kerendia grew 64.9%.

Those gains had to work against some heavy drags. Xarelto revenue fell 30.7% and Eylea 23.5%. Even so, pharma sales advanced 6.4% on a currency- and portfolio-adjusted basis — a figure that says as much about the offsetting job the new drugs are already doing as about their own momentum.

Should investors sell immediately? Or is it worth buying Bayer?

The profitability picture is where the debate starts. The pharma unit's EBITDA margin before special items hit 27.6% in the quarter, against a full-year target range of 25–27%. Bayer was explicit that investors should not treat the quarterly level as a new permanent baseline. Higher expected launch costs for Asundexian could weigh on margins from here.

That caveat matters because the raised earnings guidance, strong as it is, does not settle the underlying question: how much of this earning power can be carried forward? The yardstick is the pharma margin after those added launch costs — proof that the new growth drivers can absorb both the decline of older products and the expense of further launches, not merely generate revenue.

Agrochemicals and the Balance Sheet Cut the Other Way

Goldman's James Quigley sees the division at the start of a new growth phase, though he expects the agricultural chemicals unit to stay volatile for now. The bullish case, in other words, does not rest on an even recovery across the group. Pharma would have to generate enough extra earning power to cushion swings in agriculture.

Crop Science showed why. Adjusted revenue fell 2.4% to EUR 3.884 billion, and EBITDA before special items dropped 41.3% to EUR 101 million, with generic competition and weather-related pressure in crop protection standing in the way of a broader operating recovery. Consumer Health brought in EUR 1.445 million — EUR 1.445 billion in revenue, a currency- and portfolio-adjusted gain of 0.1%.

Then there is the balance sheet. Free cash flow for the first nine months was negative to the tune of EUR 3 billion, a figure that included EUR 3.7 billion in litigation payments. Net debt stood at EUR 31.1 billion at the end of the third quarter. Operating progress does not automatically translate into financial room to maneuver while legal disputes absorb that kind of cash.

Morningstar takes a far more cautious view of the valuation, putting fair value at EUR 52 per share, calling Bayer fairly valued and flagging high uncertainty. The gap between that anchor and the EUR 66 targets shows how much of the call hinges on how durable the pharma upswing is assumed to be.

Bayer at a turning point? This analysis reveals what investors need to know now.

Two Dates to Watch Before Year-End

For the full year, Bayer expects currency-adjusted EBITDA before special items of EUR 9.8–10.3 billion and has raised its free cash flow outlook to minus EUR 1.5 billion to minus EUR 0.5 billion.

A US decision on Sunharbo is expected in November, according to Morningstar, and could shape how the market reads the next stage of the pharma story. Final court approval of the proposed Roundup settlement is anticipated before Christmas. Neither outcome is priced in yet.

What would make the bull case convincing is not a repeat of the quarter's peak margin but a pharma margin that holds inside Bayer's own range even as launch costs rise — paired with legal relief that frees up financial headroom. Revenue growth and profitability standing up together, in other words, rather than either one alone.

Ad

Bayer Stock: New Analysis - 4 November

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...